The patient’s somatic tumor testing was notable for proficient DNA mismatch repair status, microsatellite stability, low tumor mutational burden (4 mut/Mb), low loss of heterozygosity (9%), amplification of the ERBB2 (Her2/Neu) gene by both immunohistochemistry (3+, 20% positive) and fluorescence in-situ hybridization. Here, ERBB2 is linked to neoplasm.